Repare Therapeutics Inc. (RPTX)

USD 0.91

(1.33%)

Market Cap (In USD)

38.76 Million

Revenue (In USD)

51.13 Million

Net Income (In USD)

-93.79 Million

Avg. Volume

239.27 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.225-8.49
PE
-0.46
EPS
-2.0
Beta Value
0.713
ISIN
US7602731025
CUSIP
760273102
CIK
1808158
Shares
42510700.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lloyd Mitchell Segal
Employee Count
-
Website
https://www.reparerx.com
Ipo Date
2020-06-19
Details
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.